Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Sponsors: Update Your FDA Contacts List

Executive Summary

New policy allows more FDA staffers to answer certain questions about pending applications, rather than channeling them all through the regulatory project manager.

You may also be interested in...



GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began

Generic drug reviews during the first year of formal review goals cost 70% more than during GDUFA's inaugural year.

GDUFA Stakeholder Deadline May Come After Negotiations Conclude

Generic drug user fee reauthorization talks remain on schedule and are expected to last about four months.

To Prevent Shortages, US FDA Wants Sponsor To Provide Notifications Of Demand Spike

Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS057082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel